Free Trial

Eagle Pharmaceuticals (EGRX) Competitors

Eagle Pharmaceuticals logo
$1.49 -0.01 (-0.67%)
As of 02/21/2025 09:52 AM Eastern

EGRX vs. OPTN, RVPH, OTLK, PDSB, VNRX, ALXO, IMRX, ACHL, FGEN, and IMMX

Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include OptiNose (OPTN), Reviva Pharmaceuticals (RVPH), Outlook Therapeutics (OTLK), PDS Biotechnology (PDSB), VolitionRx (VNRX), ALX Oncology (ALXO), Immuneering (IMRX), Achilles Therapeutics (ACHL), FibroGen (FGEN), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.

Eagle Pharmaceuticals vs.

OptiNose (NASDAQ:OPTN) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.

Eagle Pharmaceuticals has a net margin of 0.00% compared to OptiNose's net margin of -41.16%.

Company Net Margins Return on Equity Return on Assets
OptiNose-41.16% N/A -27.42%
Eagle Pharmaceuticals N/A N/A N/A

OptiNose has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

85.6% of OptiNose shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 2.3% of OptiNose shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, OptiNose had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for OptiNose and 0 mentions for Eagle Pharmaceuticals. OptiNose's average media sentiment score of 1.94 beat Eagle Pharmaceuticals' score of 0.00 indicating that OptiNose is being referred to more favorably in the media.

Company Overall Sentiment
OptiNose Very Positive
Eagle Pharmaceuticals Neutral

OptiNose presently has a consensus target price of $16.67, suggesting a potential upside of 188.85%. Given OptiNose's stronger consensus rating and higher probable upside, equities research analysts plainly believe OptiNose is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OptiNose
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Eagle Pharmaceuticals has higher revenue and earnings than OptiNose.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiNose$70.99M0.82-$35.48M-$4.20-1.37
Eagle Pharmaceuticals$316.61M0.06$35.64MN/AN/A

Eagle Pharmaceuticals received 163 more outperform votes than OptiNose when rated by MarketBeat users. Likewise, 66.67% of users gave Eagle Pharmaceuticals an outperform vote while only 63.68% of users gave OptiNose an outperform vote.

CompanyUnderperformOutperform
OptiNoseOutperform Votes
249
63.68%
Underperform Votes
142
36.32%
Eagle PharmaceuticalsOutperform Votes
412
66.67%
Underperform Votes
206
33.33%

Summary

Eagle Pharmaceuticals beats OptiNose on 8 of the 15 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EGRX vs. The Competition

MetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$19.36M$7.04B$5.77B$8.98B
Dividend YieldN/A2.87%4.78%3.85%
P/E RatioN/A6.1326.4618.82
Price / Sales0.06309.83453.2580.30
Price / Cash0.3167.8344.0437.47
Price / BookN/A6.747.634.64
Net Income$35.64M$138.11M$3.18B$245.69M
7 Day Performance27.35%-2.43%-1.91%-2.66%
1 Month Performance98.67%-1.91%-0.19%-2.15%
1 Year Performance-74.62%-5.03%16.70%12.90%

Eagle Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EGRX
Eagle Pharmaceuticals
N/A$1.49
-0.7%
N/A-76.1%$19.36M$316.61M0.00100
OPTN
OptiNose
4.2591 of 5 stars
$6.00
+6.8%
$16.67
+177.8%
-71.3%$60.36M$70.99M-1.43190Positive News
RVPH
Reviva Pharmaceuticals
3.4487 of 5 stars
$1.80
flat
$11.40
+533.3%
-63.1%$60.19MN/A-1.625
OTLK
Outlook Therapeutics
2.0784 of 5 stars
$1.87
+1.6%
$27.40
+1,365.2%
-81.3%$59.80MN/A-0.2120Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
PDSB
PDS Biotechnology
1.0401 of 5 stars
$1.56
+4.0%
$11.67
+647.9%
-74.7%$58.36MN/A-1.3420News Coverage
Gap Up
VNRX
VolitionRx
1.863 of 5 stars
$0.63
+9.1%
$3.75
+498.1%
-43.1%$58.10M$1.29M-1.7480
ALXO
ALX Oncology
3.4091 of 5 stars
$1.10
+1.9%
$3.05
+177.3%
-93.0%$58.01MN/A-0.3740
IMRX
Immuneering
3.0181 of 5 stars
$1.86
flat
$12.20
+555.9%
-72.6%$57.75M$320,000.00-0.9460
ACHL
Achilles Therapeutics
2.6731 of 5 stars
$1.38
-0.7%
$4.00
+189.9%
+12.2%$56.72MN/A-0.84250High Trading Volume
FGEN
FibroGen
4.5079 of 5 stars
$0.55
+6.5%
N/A-58.8%$55.88M$147.75M-0.45570Upcoming Earnings
Analyst Forecast
Short Interest ↓
News Coverage
Gap Down
IMMX
Immix Biopharma
2.6059 of 5 stars
$1.98
-0.5%
$7.00
+253.5%
-41.1%$54.47MN/A-2.339

Related Companies and Tools


This page (NASDAQ:EGRX) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners